Novartis to supply cholesterol drug to high-risk patients in the UK

Drug giant Novartis reached a deal with the U.K. government to provide its drug, Inclisiran, to patients at high risk of heart attack, CNBC reported. 

Inclisiran is a late-stage cholesterol drug designed to treat patients with atherosclerosis, a heart disease in which plaque builds up in arteries that can lead to heart attack, stroke or death. 

Novartis acquired the drug, which is pending approval in the U.S., as part of its $9.7 billion acquisition of The Medicines Company. It is intended to be used along with statins for patients who struggle to lower their cholesterol using traditional therapy. 

Inclisiran will be provided on a "population basis" to atherosclerosis patients in the U.K. after it is tested  in a large clinical trial and approved, according to CNBC

Novartis hasn't released the financial details of the deal. 

Read the full article here

More articles on pharmacy:
Roche pulled a $1.5B fast one on US, whistleblower physician alleges
CVS adds 15 HealthHUBs to Houston area
Nationwide Children's to build gene therapy biofactory, create more than 100 jobs

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months